Horizon Pharma PLC

HZNP

NASDAQ. Currency in USD

112.97 +0.09 ( +0.08% )

Real time prices: December 19

Market Cap.
25.64B
Beta (5Y monthly)
1.22
Price/Earnings
19.11
EPS (TTM)
5.07
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
2.82M
1y Target Est.
111.50
Day's Range
112.90
-
113.27
52 Week's Range
57.84
-
117.49

Historical Summary

Performance
EPS growth
Share Buybacks

About Horizon Pharma PLC

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.horizontherapeutics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
226.82M
Employees
2095
Address
70 St. Stephen?s Green, Dublin, Ireland, 2
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Latest news

Wall Street Breakfast: What Moved Markets
Wall Street Breakfast: What Moved Markets

Listen on the go! A daily podcast of Wall Street Breakfast will be available this...
By Seeking Alpha - 6 weeks ago

Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More

Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during...
By Zacks Investment Research - 7 weeks ago

Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?

The most overbought stocks in the healthcare sector presents an opportunity to go short on...
By Benzinga - 7 weeks ago

Amgen to Buy Horizon Therapeutics: ETFs to Bet On
Amgen to Buy Horizon Therapeutics: ETFs to Bet On

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put...
By Zacks Investment Research - 7 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022

Upgrades For Equinix Inc (NASDAQ:EQIX), Cowen & Co. upgraded the previous rating of Market Perform...
By Benzinga - 7 weeks ago

Company News for Dec 13, 2022
Company News for Dec 13, 2022

Companies in The News Are: COUP,HZNP,AMGN,RIVN,BA
By Zacks Investment Research - 7 weeks ago

Amgen wins battle for Horizon Therapeutics, bolstering its rare-disease portfolio
Amgen wins battle for Horizon Therapeutics, bolstering its rare-disease portfolio

Amgen Inc. is acquiring Dublin-based Horizon Therapeutics in a roughly $28 billion deal that is...
By MarketWatch - 7 weeks ago

Cramers Says These 3 Big Deals Aided Monday's Market Rally: 'When Companies Start Buying Each Other At A Big Premium...'
Cramers Says These 3 Big Deals Aided Monday's Market Rally: 'When Companies Start Buying Each Other At A Big Premium...'

Prominent market commentator Jim Cramer said three corporate deals announced on Monday aided the rally...
By Benzinga - 7 weeks ago